New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension
International Journal of Cardiology Hypertension · 2019
DOI: 10.1016/j.ijchy.2019.100022 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cardiology Hypertension, 2019. Verfasst von Vasilios Papademetriou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Georgetown University and VA Medical Center, Washington DC, USA. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: following the publication of SYMPLICITY HTN-3 the field of renal of denervation was put on hold. Although SYMPLICITY HTN-3 was well-designed and sham-controlled trial it failed to show any meaningful reduction in office or 24 h ambulatory blood pressure. The procedure was however safe and allowed research to continue. Although several pitfalls of the study have been pointed out, incomplete renal denervation was also implicated. Since then, a great deal of basic and clinical research took place and will be briefly commented on in this article. METHODS AND RESULTS: Before and after SYMPLICITY-HTN-3, numerous uncontrolled, single or unblinded studies have shown substantial office BP reduction ranging from -7.7 to -32 mmHg and ambulatory BP ranging from -2.2 to 10.2 mmHg. Average weighted office systolic BP reduction was -20.8 mmHg and weighted average 24 h ambulatory BPM reduction was -7.8 mmHg. National and international registries have shown similar BP reductions, but results remained unconvincing due to lack of reliable sham controls. In recent years, 5 well-designed sham - controlled studies (beyond, SYMPLICITY-HTN-3) have been published. Of those studies two were single center and three were multicenter international studies. Four studies used single tip or multi-electrode, radiofrequency catheters and one used focused ultrasound. The three multicenter studies reported positive-placebo subtracted results and established BP reductions measured both in the office and by ambulatory monitoring. No serious adverse events were reported. CONCLUSIONS: It can therefore be concluded that the latest sham controlled studies established efficacy and safety of renal denervation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Georgetown University and VA Medical Center, Washington DC, USA.
- Aristotle University, Thessaloniki, Greece.
- University Hospital Erlangen, Friedrich Alexander University, Erlangen/Nuremberg, Germany.
- Clinique Pasteur, Hypertension, Risk Factors and Heart Failure Unit, INSERM 1048, Clinical Research Center, Toulouse, France.
- National and Kapodistrian University, Athens, Greece.
Zitieren
APA
Papademetriou, V., Stavropoulos, K., Imprialos, K., Doumas, M., Schmieder, R. E., Pathak, A., & Tsioufis, C. (2019). New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. International Journal of Cardiology Hypertension. https://doi.org/10.1016/j.ijchy.2019.100022
Vancouver
Papademetriou V, Stavropoulos K, Imprialos K, Doumas M, Schmieder RE, Pathak A, et al. New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. International Journal of Cardiology Hypertension. 2019. doi:10.1016/j.ijchy.2019.100022
BibTeX
@article{Papademetriou2019,
author = {Papademetriou, Vasilios and Stavropoulos, Konstantinos and Imprialos, Kostas and Doumas, Michael and Schmieder, Roland E and Pathak, Atul and Tsioufis, Costas},
title = {New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension},
journal = {International Journal of Cardiology Hypertension},
year = {2019},
doi = {10.1016/j.ijchy.2019.100022}
}
EUVIMED